247 related articles for article (PubMed ID: 37290799)
21. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
22. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
23. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Gordon LI
Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
[TBL] [Abstract][Full Text] [Related]
24. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
[TBL] [Abstract][Full Text] [Related]
25. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
27. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
[TBL] [Abstract][Full Text] [Related]
28. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Emmanouilides C; Witzig TE; Gordon LI; Vo K; Wiseman GA; Flinn IW; Darif M; Schilder RJ; Molina A
Leuk Lymphoma; 2006 Apr; 47(4):629-36. PubMed ID: 16690521
[TBL] [Abstract][Full Text] [Related]
29. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Werner R; Haug A; Buske C; Heidegger S; Illert AL; Bassermann F; Herhaus P; Buck A; Duell J; Topp MS; Kraus S; Einsele H; Lapa C; Raderer M; Lenz G; Habringer S; von Tresckow B; Keller U
Nuklearmedizin; 2024 Apr; 63(2):57-61. PubMed ID: 38190998
[TBL] [Abstract][Full Text] [Related]
30. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
[TBL] [Abstract][Full Text] [Related]
31. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
[TBL] [Abstract][Full Text] [Related]
33. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report.
Papajik T; Prochazka V; Raida L; Kubova Z; Myslivecek M; Drymlova J; Buriankova E; Kucerova L; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):109-12. PubMed ID: 17690751
[TBL] [Abstract][Full Text] [Related]
34. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Ansell SM; Schilder RJ; Pieslor PC; Gordon LI; Emmanouilides C; Vo K; Czuczman MS; Witzig TE; Theuer C; Molina A
Clin Lymphoma; 2004 Dec; 5(3):202-4. PubMed ID: 15636698
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Leahy MF; Turner JH
Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
[TBL] [Abstract][Full Text] [Related]
36. Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab.
Sjögreen-Gleisner K; Dewaraja YK; Chiesa C; Tennvall J; Lindén O; Strand SE; Ljungberg M
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):126-54. PubMed ID: 21386787
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM
Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981
[TBL] [Abstract][Full Text] [Related]
38. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Weigert O; Illidge T; Hiddemann W; Dreyling M
Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
[TBL] [Abstract][Full Text] [Related]
39. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Wiseman GA; Gordon LI; Multani PS; Witzig TE; Spies S; Bartlett NL; Schilder RJ; Murray JL; Saleh M; Allen RS; Grillo-López AJ; White CA
Blood; 2002 Jun; 99(12):4336-42. PubMed ID: 12036859
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy in follicular lymphoma.
Illidge T; Morschhauser F
Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
